Free Trial
→ Trump’s New Dollar revealed (From Porter & Company) (Ad)tc pixel Free RGC Stock Alerts

Regencell Bioscience (RGC) Competitors

Regencell Bioscience logo
$19.99 -2.17 (-9.79%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$20.25 +0.26 (+1.31%)
As of 06/5/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RGC vs. TEVA, RVMD, ONC, BNTX, and INSM

Should you buy Regencell Bioscience stock or one of its competitors? MarketBeat compares Regencell Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Regencell Bioscience include Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), BioNTech (BNTX), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Regencell Bioscience compare to Teva Pharmaceutical Industries?

Regencell Bioscience (NASDAQ:RGC) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 22.11%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Teva Pharmaceutical Industries
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Teva Pharmaceutical Industries has higher revenue and earnings than Regencell Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
Teva Pharmaceutical Industries$17.26B2.28$1.41B$1.3325.72

Regencell Bioscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Regencell Bioscience's net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Regencell Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
Teva Pharmaceutical Industries 9.01%43.53%8.19%

In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than Regencell Bioscience. MarketBeat recorded 28 mentions for Teva Pharmaceutical Industries and 17 mentions for Regencell Bioscience. Teva Pharmaceutical Industries' average media sentiment score of 1.22 beat Regencell Bioscience's score of 0.01 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regencell Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
17 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Teva Pharmaceutical Industries
21 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Regencell Bioscience on 11 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Regencell Bioscience (NASDAQ:RGC) are both large-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Regencell Bioscience has lower revenue, but higher earnings than Revolution Medicines.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$11.58M2,739.75-$1.13B-$7.07N/A
Regencell BioscienceN/AN/A-$3.58MN/AN/A

Regencell Bioscience's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A -83.22% -59.06%
Regencell Bioscience N/A N/A N/A

Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

In the previous week, Revolution Medicines had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 19 mentions for Revolution Medicines and 17 mentions for Regencell Bioscience. Revolution Medicines' average media sentiment score of 0.42 beat Regencell Bioscience's score of 0.01 indicating that Revolution Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revolution Medicines
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Regencell Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
17 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Revolution Medicines presently has a consensus price target of $123.72, suggesting a potential downside of 17.09%. Given Revolution Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Revolution Medicines is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
3 Strong Buy rating(s)
3.00
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Revolution Medicines beats Regencell Bioscience on 9 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to BeOne Medicines?

Regencell Bioscience (NASDAQ:RGC) and BeOne Medicines (NASDAQ:ONC) are both large-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Regencell Bioscience has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Regencell Bioscience's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Regencell Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
BeOne Medicines 8.94%12.06%6.69%

In the previous week, Regencell Bioscience had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Regencell Bioscience and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.79 beat Regencell Bioscience's score of 0.01 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regencell Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
17 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BeOne Medicines
2 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

BeOne Medicines has higher revenue and earnings than Regencell Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
BeOne Medicines$5.34B5.55$286.93M$4.4760.43

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 44.39%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BeOne Medicines
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

Summary

BeOne Medicines beats Regencell Bioscience on 12 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to BioNTech?

Regencell Bioscience (NASDAQ:RGC) and BioNTech (NASDAQ:BNTX) are both large-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Regencell Bioscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

In the previous week, Regencell Bioscience had 9 more articles in the media than BioNTech. MarketBeat recorded 17 mentions for Regencell Bioscience and 8 mentions for BioNTech. BioNTech's average media sentiment score of 0.46 beat Regencell Bioscience's score of 0.01 indicating that BioNTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regencell Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
17 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioNTech
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Regencell Bioscience has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. Regencell Bioscience's return on equity of 0.00% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
BioNTech -44.39%-5.30%-4.62%

Regencell Bioscience has higher earnings, but lower revenue than BioNTech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
BioNTech$3.25B6.86-$1.29B-$5.88N/A

BioNTech has a consensus price target of $129.56, suggesting a potential upside of 47.10%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioNTech
1 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.74

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

BioNTech beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Insmed?

Regencell Bioscience (NASDAQ:RGC) and Insmed (NASDAQ:INSM) are both large-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Insmed had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 21 mentions for Insmed and 17 mentions for Regencell Bioscience. Insmed's average media sentiment score of 0.88 beat Regencell Bioscience's score of 0.01 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regencell Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
17 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Insmed
14 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Regencell Bioscience has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Regencell Bioscience's return on equity of 0.00% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
Insmed -144.44%-130.11%-51.57%

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Insmed has a consensus price target of $210.50, indicating a potential upside of 123.41%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Insmed
1 Sell rating(s)
0 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.96

Regencell Bioscience has higher earnings, but lower revenue than Insmed.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
Insmed$819.56M24.92-$1.28B-$5.75N/A

Regencell Bioscience has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Summary

Insmed beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGC vs. The Competition

Export
MetricRegencell BioscienceMedicinal Chemicals IndustryManufacturing SectorNASDAQ Exchange
Market Cap$10.96B$5.48B$4.83B$12.42B
Dividend YieldN/AN/A8.16%5.34%
P/E RatioN/AN/A21.7523.63
Price / SalesN/A0.46128.53137.68
Price / CashN/A1.2452.8757.17
Price / Book1,999.00999.9027.926.35
Net Income-$3.58M-$1.41M$109.80M$337.59M
7 Day Performance-16.36%-16.36%0.56%-2.51%
1 Month Performance-27.55%-27.55%0.08%-0.69%
1 Year PerformanceN/AN/A12.31%25.37%

Regencell Bioscience Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGC
Regencell Bioscience
0.16 of 5 stars		$19.99
-9.8%		N/AN/A$10.96BN/AN/A10
TEVA
Teva Pharmaceutical Industries
4.853 of 5 stars		$32.72
-1.1%		$41.78
+27.7%		+98.5%$38.04B$17.26B24.6033,950
RVMD
Revolution Medicines
2.306 of 5 stars		$155.99
+3.1%		$123.72
-20.7%		+271.2%$32.17B$11.58MN/A250
ONC
BeOne Medicines
4.5078 of 5 stars		$279.00
+1.6%		$390.00
+39.8%		+5.1%$30.14B$5.34B61.4512,000
BNTX
BioNTech
4.0048 of 5 stars		$88.45
-0.8%		$129.56
+46.5%		-20.0%$22.54B$3.25BN/A7,807

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RGC) was last updated on 6/6/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
BUY THIS: Claim a backdoor stake in SpaceX before June 12
Marc Chaikin, the Wall Street veteran who spotted Nvidia before a 45,000% run, says there's a simple trade ava...
Chaikin Analytics | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
How to get into the SpaceX IPO before June 12
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel
One page of the SpaceX S-1 will move this stock overnight
When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...
Behind the Markets | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel